Daily Brief Health Care: BeiGene Ltd, Genmab A/S, InMed Pharmaceuticals and more

In today’s briefing:

Quiddity Leaderboard for Hang Seng Index Sep 23: Beigene Vs Peers An Interesting Trade
Genmab A/S (GMAB US): Darzalex Continued to Be the Cash Cow; Epkinly Approval Adds Another Catalyst
UPDATE NOTE – InMed Pharmaceuticals, Inc. – July 6, 2023

Quiddity Leaderboard for Hang Seng Index Sep 23: Beigene Vs Peers An Interesting Trade

In this insight, we take a look at some of the names with high likelihood of being involved in index changes for the Hang Seng Index in September 2023.
The index changes for the September 2023 rebalance could be announced in mid-August and implemented in early-September.
Although the index methodology is highly subjective and predicting index changes is extremely tricky, the HSI is an important index in the region and here are our thoughts for September.

Genmab A/S (GMAB US) recorded 30% YoY growth in royalty revenue on net sales of Darzalex to DKK1,952 million, representing 68% of total revenue in 1Q23.
Genmab has guided for 2023 Darzalex royalty revenue of DKK10.4–11.1B, compared to royalty revenue of DKK10.1B in 2022, based on estimated Darzalex 2023 net sales of $9.4 – 10.0B.
In May 2023, Genmab received FDA approval for Epkinly as the first and only T-cell engaging bispecific antibody for the treatment of relapsed or refractory diffuse large B-cell lymphoma.

The bottom line from the INM-755 Phase II study’s top-line results.
InMed published top-line data for its most advanced drug development program, INM-755, a cannabinol (CBN)-based topical skin cream to treat symptoms associated with a rare genetic dermatological condition called epidermolysis bullosa (EB).
Using a wide lens approach, the Phase II study produced sufficient clinically important chronic itch relief data to support a pathway to further development and potentially bigger commercial opportunities.

💡 Before it’s here, it’s on Smartkarma

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network